fingolimod has been researched along with sphingosine 1-phosphate in 12 studies
| Studies (fingolimod) | Trials (fingolimod) | Recent Studies (post-2010) (fingolimod) | Studies (sphingosine 1-phosphate) | Trials (sphingosine 1-phosphate) | Recent Studies (post-2010) (sphingosine 1-phosphate) |
|---|---|---|---|---|---|
| 65 | 0 | 51 | 3,796 | 23 | 2,148 |
| Protein | Taxonomy | fingolimod (IC50) | sphingosine 1-phosphate (IC50) |
|---|---|---|---|
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | 0.0019 | |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | 0.0522 | |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | 0.0008 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.023 | |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | 0.0004 | |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ann Keohane, C; Bergstrom, J; Card, D; Chrebet, G; Hajdu, R; Hale, JJ; Jackson, JJ; Koo, GC; Koprak, SL; Mandala, S; Milligan, J; Mills, SG; Neway, W; Rosen, H; Rosenbach, M; Shei, GJ | 1 |
| Bergstrom, J; Card, D; Chrebet, G; Ferrer, M; Hajdu, R; Hale, JJ; Hodder, P; Keohane, CA; Lynch, CL; Mandala, S; Milligan, JA; Mills, SG; Neway, W; Parent, SA; Rosen, H; Rosenbach, MJ; Shei, GJ; Strulovici, B | 1 |
| Billich, A; Charron, G; Guerini, D; Hanessian, S | 1 |
| Black, C; Chollate, S; Guckian, KM; Hahm, K; Hetu, G; Jin, P; Kumaravel, G; Lee, WC; Lin, EY; Luo, Y; Lynch, KR; Ma, B; Macdonald, TL; Rohde, E; Rossomando, A; Scannevin, R; Scott, D; Wang, J; Yang, C | 1 |
| Arnett, HA; Cee, VJ; Croghan, MD; Fiorino, M; Fotsch, C; Frohn, MJ; Harrington, PE; Horner, M; Lanman, BA; Lee, MR; McElvain, M; Morrison, HG; Pennington, LD; Pickrell, AJ; Reed, AB; Sham, KK; Tasker, AS; Wong, M; Xu, H; Xu, Y; Zhang, X | 1 |
| Bernier, SG; Deng, H; Doyle, E; Evindar, G; Lorusso, J; Morgan, BA; Westlin, WF | 2 |
| Al-Shamma, H; Anthony, T; Barden, J; Behan, DP; Blackburn, A; Buzard, DJ; Calderon, I; Calvano, L; Chen, C; Chen, W; Christopher, RJ; Edwards, J; Fu, L; Gaidarov, I; Gao, Y; Gatlin, J; Gharbaoui, T; Han, S; Jones, RM; Kawasaki, A; Kim, SH; Le, M; Lehmann, J; Lopez, L; Ma, YA; Mills, D; Montalban, AG; Moody, J; Morgan, M; Rueter, J; Sadeque, A; Sage, C; Semple, G; Sengupta, D; Solomon, M; Stirn, S; Thatte, J; Thoresen, L; Ullman, B; Unett, DJ; Usmani, K; Whelan, K; Zhu, X | 1 |
| Al-Shamma, H; Anthony, T; Barden, J; Behan, DP; Blackburn, A; Buzard, DJ; Calvano, L; Chen, C; Chen, W; Christopher, RJ; Edwards, J; Fu, L; Gaidarov, I; Gao, Y; Gatlin, J; Gharbaoui, T; Johnson, B; Jones, RM; Kasem, M; Kawasaki, A; Kim, SH; Krishnan, A; Le, M; Lopez, L; Moody, J; Morgan, M; Sadeque, A; Schrader, TO; Semple, G; Sengupta, D; Solomon, M; Stirn, S; Thatte, J; Thoresen, L; Unett, DJ; Usmani, K; Whelan, K; Zhu, X | 1 |
| Haufe, G; Keul, P; Levkau, B; Schäfers, M; Shaikh, RS | 1 |
| Bannen, LC; Betageri, R; Chan, DS; DiSalvo, D; Fletcher, K; Harcken, C; Hickey, E; Hill-Drzewi, M; Hopkins, TD; Horan, JC; Kemper, RA; Kuzmich, D; Lemieux, RM; Levin, JI; Linehan, B; Liu, P; Lord, J; Mac, MB; Mao, C; Miller, C; Modis, LK; Ng, S; Patel, M; Patenaude, L; Smith, D; Studwell, D; Terenzzio, D; Wang, Y; Xia, H; Xu, W; Yu, H | 1 |
| Balimane, P; Banas, D; Barrish, JC; Carter, PH; Cornelius, G; Cvijic, ME; D'Arienzo, C; Dyckman, AJ; Gillooly, K; Guo, J; Langevine, CM; Liu, R; Marino, A; McIntyre, KW; McKinnon, M; Moquin, RV; Pitts, WJ; Rex-Rabe, S; Salter-Cid, L; Shen, DR; Shuster, DJ; Spergel, SH; Suchard, SJ; Taylor, T; Warrack, B; Watterson, SH; Xie, J; Yarde, M | 1 |
12 other study(ies) available for fingolimod and sphingosine 1-phosphate
| Article | Year |
|---|---|
Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720.
Topics: Animals; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Injections, Intravenous; Male; Mice; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2004 |
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
Topics: Administration, Oral; Animals; Azetidines; Biological Availability; CHO Cells; Cricetinae; Dogs; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Lymphocytes; Macaca mulatta; Mice; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2004 |
Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
Topics: Animals; Aza Compounds; Calcium; Cell Line; CHO Cells; Chromatography, Thin Layer; Cricetinae; Cricetulus; Cytoplasm; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indicators and Reagents; Magnetic Resonance Spectroscopy; Molecular Probes; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; Immunosuppressive Agents; Lymphopenia; Mice; Models, Molecular; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Receptors, Lysosphingolipid; Structure-Activity Relationship; Tetrahydronaphthalenes | 2010 |
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2012 |
Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1.
Topics: Administration, Oral; Amino Acids; Animals; Inhibitory Concentration 50; Lymphopenia; Mice; Molecular Structure; Protein Binding; Receptors, Lysosphingolipid | 2013 |
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
Topics: | 2013 |
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Topics: | 2014 |
(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.
Topics: | 2014 |
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
Topics: Animals; B-Lymphocytes; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; CHO Cells; Cricetulus; Fatty Alcohols; Fingolimod Hydrochloride; Hydrocarbons, Fluorinated; Immunosuppressive Agents; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors | 2015 |
Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.
Topics: Animals; Brain; Glutamic Acid; Hep G2 Cells; Humans; Hydrogen Bonding; Kinetics; Oxadiazoles; Rats; Receptors, Lysosphingolipid; Solubility; Structure-Activity Relationship; Thiadiazoles | 2016 |
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.
Topics: Animals; Arthritis, Experimental; Cell Movement; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppressive Agents; Isoxazoles; Lymphatic System; Lymphocytes; Lysophospholipids; Mice; Mice, Inbred C57BL; Rats; Rats, Inbred Lew; Sphingosine; Structure-Activity Relationship; Thymus Gland | 2016 |